Cigna AI Chief Focuses on Leading in AI Age

Cigna Group's Chief Data, Digital and AI Officer, Katya Andresen, who joined the company in September 2021, is steering Cigna's approach to artificial intelligence by reframing the central question from "how do I use AI?" to "how do I lead in an age of AI?" This strategic shift emphasizes measurement and demonstrable impact on health outcomes over the mere adoption of AI functionalities or the pursuit of numerous use cases. Andresen's philosophy centers on leveraging AI to achieve tangible improvements in patient care and operational efficiency within the healthcare sector.

Under this leadership, Cigna has announced significant projected cost savings and investments in AI technologies. This summer, the company projected that its AI and predictive analytics tools, designed to assist patients in identifying chronic conditions such as cancer, kidney disease, and high-risk pregnancies, could generate an estimated $200 million in savings over the next three years. This is achieved by proactively connecting at-risk patients with appropriate clinicians. The proactive identification and intervention aim to manage these conditions more effectively and prevent costly escalations.

Further underscoring Cigna's commitment to AI, the company announced a substantial investment of $100 million, to be deployed through 2028. This funding is specifically allocated to utilizing AI to streamline administrative tasks for clinicians, thereby reducing the time they spend on case documentation. Additionally, the investment aims to accelerate the prescription process, which can lead to faster patient access to necessary medications. These initiatives are designed to alleviate clinician burnout and improve the overall patient experience.

Andresen also highlighted a specific AI application focused on enhancing patient understanding of biosimilars. Biosimilars offer a cost-effective alternative to biologics for treating chronic diseases, though they differ from generic drugs in that they are not exact replicas due to their production from living organisms. Cigna is employing AI to better analyze common patient inquiries regarding biosimilars, aiming to provide clearer information and facilitate informed treatment decisions. This initiative addresses a critical need for patient education in navigating complex and potentially more affordable treatment options, thereby contributing to both cost reduction and improved patient engagement with their healthcare.